Related Experiment Video
Updated: Aug 11, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Management of postmenopausal women who have hyperlipidemia
1George Washington University Medical Center, School of Medicine and Health Sciences, Washington, DC 20037.
Insights
Dyslipoproteinemia affects both men and women, increasing risks for atherosclerosis and coronary artery disease (CAD). Cholesterol lowering in women, similar to men, can reduce CAD risk and improve coronary atherosclerosis.
Area of Science:
- Cardiovascular Medicine
- Lipidology
- Public Health
Background:
- Dyslipoproteinemia is a common condition affecting both genders.
- It significantly contributes to premature atherosclerosis and coronary artery disease (CAD) morbidity and mortality.
- Clinical evidence for cholesterol-lowering benefits in women is less extensive than in men but exists.
Purpose of the Study:
- To examine the impact of cholesterol lowering on cardiovascular outcomes in women.
- To compare the effects of lipid management in women with those observed in men.
- To assess the relationship between cholesterol reduction and coronary atherosclerosis regression in women.
Main Methods:
- Review of existing clinical evidence and studies on dyslipoproteinemia in women.
- Analysis of data correlating cholesterol-lowering interventions with CAD risk factors.
- Evaluation of studies reporting on coronary atherosclerosis changes following lipid management.
Main Results:
- Cholesterol lowering in women is associated with a reduction in CAD risk.
- Lipid management in women demonstrates a decline in coronary artery disease incidence.
- Evidence suggests regression of coronary atherosclerosis in women undergoing cholesterol-lowering therapy.
Conclusions:
- Cholesterol lowering is beneficial for women, mirroring benefits seen in men.
- Managing dyslipoproteinemia in women can mitigate risks of atherosclerosis and CAD.
- Further research can solidify the role of lipid-lowering therapies in female cardiovascular health.
Abstract:
Dyslipoproteinemia is prevalent in women as well as in men. In both, its consequences of premature atherosclerosis and coronary artery disease (CAD) morbidity and mortality are common. Although clinical evidence of the benefits of cholesterol lowering is less abundant in women, it is not entirely absent. As in men, cholesterol lowering in women is associated with a decline in CAD risk and regression of coronary atherosclerosis.
More Related Videos
06:18An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Lipids: Dietary Sources and Requirements
Coronary Artery Disease IV: Preventive Measures
Angina IV: Management
Atherosclerosis III: Management
Atherosclerosis IV: Nursing Management